Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.

Novartis works tirelessly with third-party organizations to improve access to cancer care.

The cause of a rare, inherited, often fatal kidney disease in many patients remained elusive for years, despite multiple attempts to solve the mystery. Then in 2012, a team of researchers cracked some of the unsolved cases in just six weeks.

The Novartis Faculty of Scholars initiative connects academic researchers with deep knowledge and big ideas to scientists in its drug discovery labs.

Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.

A strong background in biological research prepared Daniel Rooks for his role in shaping the early clinical development of new medicines

Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.

Kristen Harrington-Smith discusses her work as Vice President and Head of CAR-T US at Novartis Oncology.